TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 516.48M
Enterprise Value 315.64M
Trailing P/E N/A
Forward P/E 1-2.18
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)2.54
Price/Book (mrq)5.35
Enterprise Value/Revenue 32.41
Enterprise Value/EBITDA 6-1.59

Trading Information

Stock Price History

Beta (3Y Monthly) 0.58
52-Week Change 3-77.16%
S&P500 52-Week Change 36.00%
52 Week High 35.9208
52 Week Low 31.0320
50-Day Moving Average 31.3159
200-Day Moving Average 31.5349

Share Statistics

Avg Vol (3 month) 3301.9k
Avg Vol (10 day) 3224.88k
Shares Outstanding 521.2M
Float 12.93M
% Held by Insiders 14.32%
% Held by Institutions 14.99%
Shares Short (Jun 28, 2019) 41.1M
Short Ratio (Jun 28, 2019) 43.1
Short % of Float (Jun 28, 2019) 48.46%
Short % of Shares Outstanding (Jun 28, 2019) 48.14%
Shares Short (prior month May 31, 2019) 41.03M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25/1
Last Split Date 3Sep 29, 2015

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin -168.26%
Operating Margin (ttm)-156.05%

Management Effectiveness

Return on Assets (ttm)-75.78%
Return on Equity (ttm)-990.04%

Income Statement

Revenue (ttm)6.5M
Revenue Per Share (ttm)0.45
Quarterly Revenue Growth (yoy)-11.20%
Gross Profit (ttm)-1.4M
EBITDA -9.81M
Net Income Avi to Common (ttm)-11.22M
Diluted EPS (ttm)-0.7900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)5.91M
Total Cash Per Share (mrq)0.44
Total Debt (mrq)5.07M
Total Debt/Equity (mrq)165.93
Current Ratio (mrq)2.12
Book Value Per Share (mrq)0.23

Cash Flow Statement

Operating Cash Flow (ttm)-11.74M
Levered Free Cash Flow (ttm)-8.06M